logo

For the Inventor, By the Inventor

Waltham, MA, United States of America

Dragonfly Therapeutics, Inc.

Calculating rank
USPTO Granted Patents = 15



Trademarks = 2

Forward Citations = 34

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Ann F Cheung (14 out of 14 patents)

silverMedal William Haney (13 out of 22 patents)

bronzeMedal Gregory P Chang (13 out of 13 patents)

4.  Asya Grinberg (12 out of 67 patents)

5.  Bianka Prinz (11 out of 61 patents)

6.  Bradley M Lunde (11 out of 11 patents)

7.  Daniel Fallon (5 out of 5 patents)

8.  Nicolai Wagtmann (4 out of 13 patents)

9.  Ronnie Wei (4 out of 4 patents)

10.  Steven O'Neil (4 out of 4 patents)

11.  Jean-Marie Cuillerot (2 out of 8 patents)

12.  Eva Gutierrez (2 out of 2 patents)

13.  Christopher Ryan Morgan (2 out of 2 patents)

14.  Mark DeRose (1 out of 1 patent)

15.  Avni Shah (1 out of 1 patent)


15 patents:

1. 12760105 - MULTI-SPECIFIC BINDING PROTEINS BINDING BCMA, NKG2D AND CD16 AND METHODS OF USE (2026-10-13),
2. 12384851 - Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use (2025-08-12),
3. 12384847 - Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen (2025-08-12),
4. 12378318 - Proteins binding NKG2D, CD16 and a tumor-associated antigen (2025-08-05),
5. 12377144 - Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen (2025-08-05),
6. 12275791 - Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use (2025-04-14),
7. 12264200 - Antibody variable domains targeting the NKG2D receptor (2025-04-01),
8. 12215157 - Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use (2025-02-04),
9. 12157771 - Proteins binding NKG2D, CD16 and CLEC12A (2024-12-03),
10. 12129300 - Antibody variable domains targeting the NKG2D receptor (2024-10-29),
11. 11939384 - Antibody variable domains targeting the NKG2D receptor (2024-03-26),
12. 11884733 - Antibody variable domains targeting the NKG2D receptor (2024-01-30),
13. 11884732 - Proteins binding HER2, NKG2D and CD16 (2024-01-30),
14. 11834506 - Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer (2023-12-05),
15. 11787864 - Heterodimeric Fc-fused proteins (2023-10-17),
Company Overview
Dragonfly Therapeutics, Inc. is a biotechnology company based in Waltham, MA, specializing in the development of innovative immunotherapies. The company focuses on harnessing the power of the immune system to create novel treatments for various diseases, including cancer and autoimmune disorders. By leveraging its proprietary platform, Dragonfly aims to design and manufacture biologics that enhance immune responses, offering new therapeutic options for patients. Its research encompasses a range of advanced technologies in the field of immunology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

15 Patents

#95 in Waltham, MA

#1,278 in Massachusetts

#21,085 in US

#39,991 in the World

Waltham, MA (US)
Waltham, MA, United States of America

Dragonfly Therapeutics, Inc.

Forward Citations = 34

21 inventors:

goldMedal Ann F Cheung (14 out of 14 patents)

silverMedal William Haney (13 out of 22 patents)

bronzeMedal Gregory P Chang (13 out of 13 patents)

4.  Asya Grinberg (12 out of 67 patents)

5.  Bianka Prinz (11 out of 61 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dragonfly Therapeutics, Inc.. Retrieved from https://idiyas.com/company/dragonfly-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…